Date:		September 17, 2018
Subject:	Site Visit  -  Tokai Carbon CB Plant  -  Addis, LA and meeting with Carbon Black Manufacturers

From:		Korbin Smith
      SPPD/MMG
		U.S. Environmental Protection Agency
		Research Triangle Park, NC 27711
To:		Docket

I.	Purpose
The purpose of this trip was to first meet with manufacturers of carbon black and to gather information in support of the work for the Risk and Technology Review (RTR) of 40 CFR Part 63 National Emission Standards for Hazardous Air Pollutants (NESHAP) for carbon black manufacturing (subpart YY). The second part of the visit was to tour a carbon black manufacturing plant and observe the carbon black manufacturing process. The site visit focused on identifying all possible emission sources from raw ingredients to final product, as well as any associated control devices used during carbon black production.
II.	Place and Date
	Law Offices of Liskow & Lewis
	701 Poydras Street, Suite 5000
	New Orleans, Louisiana 70139
<PHONE_NUMBER>

      Tokai Carbon CB Plant  -  Addis, LA
      5221 Sid Richardson Rd.
      Addis, LA 70710
      (Mailing address)  -  Box 267
<PHONE_NUMBER>  -  Office

      September 11, 2018
III.	Attendees
      U.S. Environmental Protection Agency (EPA)
      Korbin Smith, SPPD/MMG
      Keith Barnett, SPPD/MMG

      Liskow & Lewis / International Carbon Black Association
      Greg Johnson
	Lesley Pietras

      Orion Engineered Carbons
	Jimmy Boyd

	Tokai Carbon CB
	Long Nguyen

	Cabot Corporation
	Lauren Bradford

	Birla Carbon
	Megan Morgan
IV.	Discussion
This section presents the findings of the visit to the Tokai Carbon CB., facility in Addis, Louisiana and a meeting with carbon black member companies. The following report is divided into sections which include, member discussion, site visit background, and emissions.
Member Discussion
      The morning of September 11, 2018, EPA met with representatives of four carbon black companies and two representatives from the International Carbon Black Association (ICBA). Jimmy Boyd (Orion Engineered Carbons) gave a presentation on carbon black production and the current MACT standard.  The presentation is attached to this site visit report. In addition to the information exchanges in the presentation, the attendees noted the following:
 Industry representatives present stated the current rule overall worked for them.
 They requested a guidance document clarifying that if facilities use tail gas for fuel, that tail gas is excluded from the definition of a process vent and the associated emission limit.
 They stated that the cross references in the G-MACT can be difficult to follow, and stated that including all the requirements in a rule specific to carbon black would be less confusing.

Site Visit Background
In the afternoon, representatives from EPA, Greg Johnson of Liskow & Lewis, and Long Nguyen and David Baker of Tokai Carbon CB toured Tokai's Addis plant. This plant produces carbon black using the furnace process, which accounts for 98% of all carbon black production. The facility currently operates flares to control tail gas emissions. As part of a consent decree, the Addis plant will be converting to an incinerator to control these emissions, but retaining the flares as a back-up if issues arise with the incinerator.

Emissions
 Fugitive Emissions
 The only expected emission point at the Addis plant are the flare stacks. These are also the only regulated emissions points.
 It is a closed process in which carbon black manufacturing from raw ingredient until packaging is done in closed pipings and machines.
 Fugitive emissions of tail gas can occur due to equipment leaks that happen prior to the flares due to the corrosive nature of tail gas. Due to the black color of the carbon black, leaks are typically identified and fixed quickly. Equipment leaks are addressed in §63.1107.
 Boiler Emissions
 Emissions from boilers at carbon black facilities are not subject to the boiler MACT. Additionally, there is not an emission limit for boilers in the carbon black MACT.


[Federal Register: January 26, 2007 (Volume 72, Number 17)]
[Notices]
[Page 3817]
[DOCID:fr26ja07-64]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP05-422-019; Docket No. RP06-226-002]

El Paso Natural Gas Company; Notice of Filing

January 17, 2007.
    Take notice that on January 10, 2007, El Paso Natural Gas Company
(EPNG) tendered filing as part of its FERC Gas Tariff, Second Revised
Volume No. 1-A, the pro forma tariff sheets listed in the attached
Appendix A to the filing.
    EPNG states that copies of the filing were served on parties on the
official service list in the above-captioned proceedings.
    Any person desiring to protest this filing must file in accordance
with Rule 211 of the Commission's Rules of Practice and Procedure (18
CFR 385.211). Protests to this filing will be considered by the
Commission in determining the appropriate action to be taken, but will
not serve to make protestants parties to the proceeding. Such protests
must be filed in accordance with the provisions of Section 154.210 of
the Commission's regulations (18 CFR 154.210). Anyone filing a protest
must serve a copy of that document on all the parties to the
proceeding.
    The Commission encourages electronic submission of protests in lieu
of paper using the ``eFiling'' link at http://www.ferc.gov. Persons

unable to file electronically should submit an original and 14 copies
of the protest to the Federal Energy Regulatory Commission, 888 First
Street, NE., Washington, DC 20426.
    This filing is accessible on-line at http://www.ferc.gov, using the

``eLibrary'' link and is available for review in the Commission's
Public Reference Room in Washington, DC. There is an ``eSubscription''
link on the Web site that enables subscribers to receive e-mail
notification when a document is added to a subscribed docket(s). For
assistance with any FERC Online service, please e-mail
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For

TTY, call<PHONE_NUMBER>.

Magalie R. Salas,
Secretary.
 [FR Doc. E7-1140 Filed 1-25-07; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 79, Number 147 (Thursday, July 31, 2014)]
[Rules and Regulations]
[Pages 44277-44278]
[FR Doc No: 2014-17912]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 520, 522, 529, and 558

[Docket No. FDA-2014-N-0002]

New Animal Drugs; Bacitracin Methylene Disalicylate; Dinoprost
Solution; Gonadorelin Hydrochloride; Progesterone Intravaginal Inserts;
Salinomycin; Ractopamine; Tylosin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval actions for new animal drug
applications (NADAs) and abbreviated new animal drug applications
(ANADAs) during June 2014. FDA is also informing the public of the
availability of summaries of the basis of approval and of environmental
review documents, where applicable. The animal drug regulations are
also being amended to remove a cross-reference to a combination drug
medicated feed that is no longer codified.

DATES: This rule is effective July 31, 2014.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for
Veterinary Medicine (HFV-6), Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855,<PHONE_NUMBER>,
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: FDA is amending the animal drug regulations
to reflect approval actions for NADAs and ANADAs during June 2014 as
listed in table 1. In addition, FDA is informing the public of the
availability, where applicable, of documentation of environmental
review under the National Environmental Policy Act (NEPA) and, for
actions requiring review of safety or effectiveness data, summaries of
the basis of approval (FOI Summaries) under the Freedom of Information
Act (FOIA). These public documents may be seen in the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m.,
Monday through Friday. Persons with access to the Internet may obtain
these documents at the Center for Veterinary Medicine (CVM) FOIA
Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. Marketing
exclusivity and patent information may be accessed in FDA's
publication, Approved Animal Drug Products Online (Green Book) at:
http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm.
    Also, the regulations are being amended in 21 CFR 558.76 to remove
a cross-reference to a combination drug medicated feed which was
removed in earlier corrections to part 558 (79 FR 10976, February 27,
2014). This amendment is being made to improve the accuracy of the
regulations.
    This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.

                  Table 1--Original and Supplemental NADAs and ANADAs Approved During June 2014
----------------------------------------------------------------------------------------------------------------
                                     New animal drug                         21 CFR        FOIA          NEPA
  NADA/  ANADA        Sponsor          product name          Action         Sections      Summary       Review
----------------------------------------------------------------------------------------------------------------
108-901........  Zoetis Inc., 333   LUTALYSE           Supplemental          522.690,  yes.........  CE\1\ \2\
                  Portage St.,       (dinoprost         approval of         522.1077,
                  Kalamazoo, MI      injection)         label references     529.1940
                  49007.             Injection.         to approved uses
                                                        with gonadorelin
                                                        hydrochloride
                                                        injection and
                                                        progesterone
                                                        intravaginal
                                                        inserts.
128-686........  Zoetis Inc., 333   BIO-COX 60         Supplemental             558.4  no..........  CE\1\ \2\
                  Portage St.,       (salinomycin       approval of
                  Kalamazoo, MI      sodium) Type A     revised assay
                  49007.             medicated          limits for Type
                                     article.           A medicated
                                                        articles.
200-473 \3\....  Huvepharma AD,     TYLOVET (tylosin   Supplemental          520.2640  no..........  CE\1\ \2\
                  5th Floor, 3A,     tartrate)          approval of a
                  Nikolay Haytov     Soluble.           change in
                  Str., 1113                            marketing status
                  Sophia, Bulgaria.                     from over-the-
                                                        counter (OTC) to
                                                        by veterinary
                                                        prescription
                                                        (Rx).
200-560........  Zoetis Inc., 333   ACTOGAIN           Original approval      558.500  yes.........  CE\1\ \2\
                  Portage St.,       (ractopamine       as a generic
                  Kalamazoo, MI      HCl), RUMENSIN     copy of NADA 141-
                  49007.             (monensin), MGA    234.
                                     (melengestrol
                                     acetate), and
                                     Type B and C
                                     medicated feeds.
200-562........  Zoetis Inc., 333   ACTOGAIN           Original approval      558.500  yes.........  CE\1\ \2\
                  Portage St.,       (ractopamine       as a generic
                  Kalamazoo, MI      HCl), RUMENSIN     copy of NADA 141-
                  49007.             (monensin),        233.
                                     TYLAN (tylosin
                                     phosphate), and
                                     MGA
                                     (melengestrol
                                     acetate) Type B
                                     and C medicated
                                     feeds.
----------------------------------------------------------------------------------------------------------------
\1\ The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the
  requirement to submit an environmental assessment or an environmental impact statement because it is of a type
  that does not individually or cumulatively have a significant effect on the human environment.
\2\ CE granted under 21 CFR 25.33(a)(1).
\3\ The application listed was identified as being affected by guidance for industry (GFI) 213, ``New
  Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water
  of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions
  with GFI 209'', December 2013.

List of Subjects

21 CFR Parts 520, 522, and 529

    Animal drugs.

21 CFR Part 558

    Animal drugs, Animal feeds.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR parts 520,
522, 529, and 558 are amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 520 continues to read as
follows:

    Authority: 21 U.S.C. 360b.

Sec.  520.2640  [Amended]

0
2. In Sec.  520.2640, in paragraphs (b)(1) and (d) remove ``No.
000986'' and in its place add ``Nos. 000986 and 016592''; and in
paragraph (b)(2) remove ``Nos. 016592 and 061623'' and in its place add
``No. 061623''.

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

0
3. The authority citation for 21 CFR part 522 continues to read as
follows:

    Authority: 21 U.S.C. 360b.

0
4. In Sec.  522.690, revise the section heading and paragraph (d)(2)(v)
to read as follows:

Sec.  522.690  Dinoprost.

* * * * *
    (d) * * *
    (2) * * *
    (v) Dinoprost injection as provided by No. 054771 in Sec.
510.600(c) of this chapter may also be used concurrently with
gonadorelin hydrochloride injection as in Sec.  522.1077 and with
progesterone intravaginal inserts as in Sec.  529.1940 of this chapter.
* * * * *

0
5. In Sec.  522.1077, revise paragraph (c)(1)(ii) to read as follows:

Sec.  522.1077  Gonadorelin hydrochloride.

* * * * *
    (c) * * *
    (1) * * *
    (ii) For use with dinoprost injection to synchronize estrous cycles
to allow fixed-time artificial insemination (FTAI) in lactating dairy
cows, administer to each cow 100 to 200 mcg gonadorelin by
intramuscular injection, followed 6 to 8 days later by 25 mg dinoprost
by intramuscular injection, followed 30 to 72 hours later by 100 to 200
mcg gonadorelin by intramuscular injection. Dinoprost injection as in
Sec.  522.690, provided by No. 054771 in Sec.  510.600(c) of this
chapter.
* * * * *

PART 529--CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

0
6. The authority citation for 21 CFR part 529 continues to read as
follows:

    Authority: 21 U.S.C. 360b.

0
7. In Sec.  529.1940, revise paragraph (d), the second sentence in
paragraph (e)(1)(i) and the last sentence in paragraph (e)(1)(iii) to
read as follows:

Sec.  529.1940  Progesterone intravaginal inserts.

* * * * *
    (d) Special considerations. Product labeling shall bear the
following warning: ``Avoid contact with skin by wearing protective
gloves when handling inserts. Store removed inserts in a sealable
container until they can be disposed of in accordance with applicable
local, state, and Federal regulations.''
    (e) * * *
    (1) * * *
    (i) * * * When used for indications listed in paragraph
(e)(1)(ii)(A) of this section, administer 25 mg dinoprost as a single
intramuscular injection 1 day prior to insert removal (Day 6). * * *
* * * * *
    (iii) * * * Dinoprost injection for use in paragraphs (e)(1)(ii)(A)
and (e)(1)(ii)(B) of this section as in Sec.  522.690 of this chapter,
provided by No. 054771 in Sec.  510.600(c) of this chapter.
* * * * *

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

0
8. The authority citation for 21 CFR part 558 continues to read as
follows:

    Authority: 21 U.S.C. 360b, 371.

Sec.  558.4  [Amended]

0
9. In paragraph (d) of Sec.  558.4, in the ``Category I'' table, in the
``Assay limits percent type A'' column, in the entry for
``Salinomycin'', remove ``95-115'' and in its place add ``90-110''.

Sec.  558.76  [Amended]

0
10. In Sec.  558.76, remove and reserve paragraph (d)(3)(vii).

Sec.  558.500  [Amended]

0
11. In Sec.  558.500, in the table in paragraphs (e)(2)(viii) and
(e)(2)(x), in the ``Sponsor'' column, remove ``000986'' and in its
place add ``000986, 054771''.

    Dated: July 24, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014-17912 Filed 7-30-14; 8:45 am]
BILLING CODE 4164-01-P


% Gender neutral or male specific values, except for female BTW and fat available
% Set sex=1 to access female parameters

SPECIES=1;
SEX=0;
PREG=0;
PAFC=0;
PAFO=0;
GDSTART=0;
BWST=70;

% Gompertz BWT Parameters (Luecke 2007)
B1=3.42826;B2=2.188189;B3=1.506303;B5=34.35453;B6=0.179781;B7=0.221175;
B4=2.462428;B8=-0.0911; AGE0=30;
AGE1=2.949004;AGE2=11;AGE3=21.66022;

if(SEX==1)
% set Female BWT Parameters
B1=3.4;B2=2.07402;B3=1.504154;B5=34.8806;B6=0.2120837;B7=0.443786;
B4=2.672665;B8=0.31127;
AGE1=2.949004;AGE2=11;AGE3=21.86533;
end

% Dynamic organ volumes
% VBC Parameters (Refit Valentine 2002 & Young 2009)
VB6=0;VB5=0;VB4=5.132e-22;VB3=-2.463e-16;VB2=4.354e-11;
VB1=-3.465e-6;VB0=1.216e-1;
% VHC (Refit Valentine 2002 & Young 2009)
VH4=1.701E-22;VH3=-7.393E-17;VH2=1.082E-11;VH1=-6.789E-7;VH0=3.917E-2;
% VBL (Young 2009)
VBL2=6.54E-13;VBL1=-3.50E-7;VBL0=8.97E-2;
% VFC (Refit, JNS w/ Valentin 2002 & Lafortuna 2005)
VF6=-2.036e-30;VF5=1.203e-24;VF4=-2.718e-19;VF3=2.892e-14;VF2=-1.422e-09;
VF1=2.803e-05;VF0=3.484e-02;
if(SEX==1)
% set Female VFC
VF6=-1.273e-30;VF5=7.249e-25;VF4=-1.558e-19;VF3=1.540e-14;VF2=-6.787e-10;
VF1=1.401e-05;VF0=9.217e-02;
end
% VAC (Fit, JNS w/ Valentin 2002 & Lafortuna 2005 fat/.8)
VA6=-2.353e-30;VA5=1.387e-24;VA4=-3.116e-19;VA3=3.268e-14;VA2=-1.542e-9;VA1=2.617e-05;
VA0=2.044e-01;
% VLC (Young 2009)
VL2=0;VL1=-4.55e-8;VL0=1.86e-2;
% VKC (Young 2009)
VK2=3.33e-13;VK1=-6.69e-8;VK0=7.26e-3;
% VSPC (Young 2009)
VSP2=0;VSP1=-5.57e-9;VSP0=3.12e-3;
% VGIC (Brown 1997, sum of stom and both intestines)
VGI3=0;VGI2=0;VGI1=0;VGI0=0.0165;
% VMC (Refit, JNS w/ Valentin 2002 & Janssen 2000)
VM4=-5.061e-21;VM3=2.052e-15;VM2=-2.865e-10;VM1=1.436e-5;VM0=1.268e-1;
% VSKC (Young 2009)
VSK5=-1.1e-27;VSK4=8.62e-22;VSK3=-2.58e-16;VSK2=3.68e-11;
VSK1=-2.56e-6;VSK0=1.03e-1;

% Constant organ volumes
VBMC=0.021;	% Brown 1997 (red only, yellow is in adipose)
VDC=0.0003;
VPC=0.00148; 	% Young 2009, Brown 1997
VINTC=0.0091;	% Just small intestine (Brown 1997)
VFETC=0,VPLAC=0,VFI=0,VFINIT=0;

% Clear doses
DT(200), DORAL(200), DSC(200), DORALO(200), AMTCDOSE(200), AMTODOSE(200);
DT=ones(size(DT))*1E6;     	% Sets all oral dose times to a long time
DORAL=zeros(size(DORAL));	% Sets all oral dose amounts to zero
DSC=zeros(size(DSC));		% Sets all SC dose amounts to zero
DORALO=zeros(size(DORALO));
AMTODOSE=zeros(size(AMTODOSE));	% Sets all oral dose amounts to zero
AMTCDOSE=zeros(size(AMTCDOSE));	% Sets all oral dose amounts to zero
CONCPPM=0.0;
CONCMGM=0.0;
CONCMG=0.0;
N=1;
VCHA=5e10;
DERM=0.0;
ORALC=0.0;
ORALO=0.0;
ORALP=0.0;
CONCL=0.0;
DERM=0;
IV=0.0;				% IV dose (ug/kg)
IVS=0.0;			% IV start time (h)
IVE=0.1;			% IV end time (h)
SCDC=0.0;			% SC dose
FEED=0.0;			% Feed dose (ug/kg feed)
FEEDR=0.0;			% Feed rate (kg/h)
FEEDT=0.0;			% Feed time
SLORAL=0.0;			% Repeated oral gavage dose
SA=100;				% Surface area exposed dermally (SQ CM)
VLIQ=1.0; 			% Volume of dose applied to skin (L)
%TSA=20466;			% Total surface area (SQ CM), human value!
TCHNG=5e55;			% Time to stop dermal exposure
%TSTOP=1

% Transfer Rates
KAS=0.;			% CPF stomach -> liver this is for rat only, set to 0 for human
KSI=0.31;	% CPF stomach -> intestine, optimized with Nolan 1984 CBLP and AE
KAI=3.1;  % CPF intestine -> liver,  optimized with Nolan 1984  CBLP and AE
KIHP=8.7;		% TCPy intestine -> liver
KOS=2;		% CPF-oxon intestine -> liver
KOSI=1.5;   %CPF-oxon from an oral dose ->intestine (OPTIMIZED IN RATS)
KSC=0.0;		% Central SC compart -> blood
KSP=0.0;		% Central SC -> peripheral SC
KPS=0.0;		% Peripheral SC -> central SC
KPL=5.5e-5;  %optimized against Nolan data
FA=1; % Fractional oral Absorption
FAD=1; %FRACTIONAL DERMAL ABSORPTION

% Small intestine metabolism parameters, Vmaxc (umol/hr/g tissue), Km (uM)
VINTTC= 53;		%parallogram approach from measured in rat liver->Intestine(Poet et al., 2003)to human
KMINTC=21; 		%  - scaling hepatic by protein content gives 53*0.39=21
VINTOC=28 ;   %parallogram approach from measured in rat liver->Intestine(Poet et al., 2003)to human
KMINTO=33.2;		% scaling hepatic by protein content = 85*0.39=33.2
VINTOXC=82 ; %parallogram approach from measured in rat liver->Intestine(Poet et al., 2003)to human
KMINTOX=192;		%  scaling hepatic by protein content 492*0.39=192

% Hepatic metabolic constants, Vmaxc (umol/hr/g tissue), Km (uM)
VMHCP=1.36e3;		% CPF -> TCP, median from Smith 2010 B
KMHCP=21; 		% Smith 2010 median; 53- scaling hepatic by protein content gives 53*0.39=21
VMHHCO=6.30E2;		% CPF -> CFP-oxon, Smith 2010 median
KMHHCO=33.2; 		% Smith 2010 median; 85 scaling hepatic by protein content = 85*0.39=33.2
VML=1.29e+05;		% CPF-oxon -> TCP, Smith 2010B median
KMLST=192; 		% Smith 2010 median; 491.8 - scaling hepatic by protein content 492*0.39=192

% Plasma metabolic constants, Vmaxc (umol/hr/L plasma), Km (uM)
VMBL1=432000;VMBL2=3.052;VMBL3=3.900;	% CPF-oxon -> TCP, logistic fit to Smith 2010 B
KMBLST=192.0;	% Smith 2010 B: 192.0 med, 203.2 mean

% Brain metabolism parameters, Vmaxc (umol/hr/g tissue), Km (uM)
VMCBCO=12.6;		% CPF -> CPF-oxon, 0.149 Extrap from Chambers 1989, 0.91 Extrap from Layshock 2009 unpub, estimated at 2% hepatic
KMBCO=33.2;		%  Same as liver
VMCBCP=27.2;		% CPF -> TCPy, Extrap from Layshock 2009 unpub
KMBCP=21;		%  Same as liver
KMBCPT=192;	%Brain oxon ->TCPy
VMBCPTC=1.94e4; %Brain oxon ->TCPy

%lung
KMOLU=33.2;		%liver
KMTLU=21	;
VMAXTLUC=1.36e3;		% LUNG CPF->TCP
VMAXOLUC=6.3e2;   % LUNG CPF->OXON
VMAXPLUC=27.2 ; %2% of liver
KMPLUC= 192;
KMUC=0.02; %OPTIMIZED IN RATS (FROM Hotchkiss inhalation report)
FRACIN=0.046;  %MPPD MODEL PREDICTed REACHING DEEP LUNG (0.233 for the mid dose per J. Hotchkiss), 20% of that optimize

% diaphragm metabolism parameters, Vmaxc (umol/hr/g tissue), Km (uM)copied from brain
VMCDPCO=12.6;		% CPF -> CPF-oxon, 2% OF HEPATIC
KMDPCO=33.2;		%  Same as intestine
VMCDPCP=27.2;		% CPF -> CPF-oxon, 2% OF HEPATIC
KMDPCP=21;		% Same as intestine

%DERMAL
VMCDERMCO=12.6;		% CPF -> CPF-oxon, 2% OF HEPATIC
KMDERMCO=33.2;		% same as hepatic
VMCDERMCP=27.2;		% CPF -> CPF-oxon, 2% OF HEPATIC. Extrap from Layshock 2009 unpub
KMDERMCP=21;	% Same as hepatic
KMDERMEST=19;	% Km CPF-oxon -> TCPy (umol/L), same as hepatic
VMDERMESTC=1.94e4;	% dermal Vmaxc CPF-oxon -> TCPy (umol/hr/kg tissue) - 10-15% of liver this is, Jewell et al Tox Let 07- general skin esterase 10% of liver in humans - Beydon et al Tox In vitro, 2010
KDIS=0.;
% TCP Excretion
KE=0.024; 		% Optimized with Nolan 1984 IBLE1 and AE

% Protein Binding
FBC=0.99;	% 0.99 Lowe 2009
FBO=0.99;	% 0.99 Lowe 2009
FUBO=0.01;
FUBC=0.01;

% Timing/Integration
MAXT=0.001;
MINT=1.0e-006;
REPTM=1.0E+6;
%POINTS=1000;

% Molecular Wts (g/mol)
MWC=350.6;
MWO=334.5;
MWP=198.0;

% HCT
HCTN=0.45; 	% 0.43 women, 0.47 men (Bresarb 1998)

% Partitioning Coef. (Lowe 2009)
% CPF
PFCN=250.0;	% Fat/blood
PHC=12.8;   	% Liver/blood
PRC=16.5;    	% Richly perfused/blood
PSC=3.85;    	% Slowly perfused/blood
PDC=3.85;    	% Diaphram/blood
PBC=16.5; 	% Brain/blood
PSK=6.8;	% Skin/Blood
PSKL=200; %liquid/skin - actually a factor of both Q and partitioning - optimized
PBL=1.0;		% Blood/blood
PLU=16.5;% Lung/blood = rapid
PLAIR=7.6e5;			%BARTELS 'generic' paper, calculated Poulen/Theil (25deg C)
PPLA=3.85; %PLACENTA=SLOW
% CPF-oxon
PFON=75.0;	% Fat/blood
PHO=4.5;   	% Liver/blood
PRO=5.6;    	% Richly perfused/blood
PSO=1.8;    	% Slowly perfused/blood
PDO=1.8;   	% Diaphram/blood
PBO=5.6;	% Brain/blood
PBLO=1;		% Blood/blood
PLUO=5.6;% Lung/blood = rapid
PLAIRO=7.6e5;	%BARTELS 'generic' paper, calculated Poulen/Theil (25deg C), ASSUME =CPF
PSKO=125;%liquid/skin - actually a factor of both Q and partitioning - =CPF
PPLAO=1.8; %PLACENTA=SLOW

% BuChE activity (umol/hr/kg tissue) (Maxwell 1987)
BBUCE=4.68e4;		% 4.68E4 Maxwell 1987
DBUCE=2.64e4;
HBUCE=3.0e4;
BLBUCE=2.63e5;		% 2.63E5 Sidell 1975
LUBUCE=8.6e4; %Maxwell, 87

% CaE activity (umol/hr/kg tissue) (Maxwell 1987)
BRCE=2.88e5;	% based on Hojring 1976 scaled by hepatic
DACE=3.18e5;
HECE=1.27e6;	 % based on Pope 2005, timchalk 02/Maxwell
PLOCE=1e-99;					% 0 Li 2005
LUECE=1.4e6; %Maxwell, 87

% AChE activity (umol/hr/kg tissue) (Maxwell 1987)
BACHE=4.40e5;		% 4.40E5 Maxwell 1987,
BLACHE=1e-99; 		% 1248 Li 2005 & Brimijoin 1988
DACHE=7.74e4;
HACHE=1.02e4;
RBCHE=4.27e5;		% 4.27E5 Albers 2009,
LUACHE=2.28e4 ;%Maxwell, '87 -

% Esterase aging rates (1/h)
KABBE=0.0113;
KABCE=0.0113;
KABCR=0.0113;
KABLBE=0.0113;
KABLCE=0.0113;
KABLCR=0.0113;
KADBE=0.0113;
KADCE=0.0113;
KADCR=0.0113;
KAHBE=0.0113;
KAHCE=0.0113;
KAHCR=0.0113;
KARBCE=0.0113;
KALUCR=0.0113;

% Degradation of esterase (1/h)
KDBBE=0.0024;
KDBCE=  0.01;
KDBCR=0.000754;
KDBLBE=0.0024;
KDBLCE=0.01;
KDBLCR=0.0033;
KDDBE=0.0024;
KDDCE=0.01;
KDDCR=0.001;
KDHBE=0.0024;
KDHCE=0.01;
KDHCR=0.001;
KDRBCE=0.01;
KDLUCE=0.01;

% Inhibition of esterase (L/umol/h)
KIBBE=2000;
KIBCE=220;
KIBCR=20;
KIBLBE=2000;
KIBLCE=220;
KIBLCR=20;
KIDBE=2000;
KIDCE=220;
KIDCR=20;
KIHBE=2000;
KIHCE=220;
KIHCR=20;
KIRBCE=100;
KILUBE=2000;
KILUCE=220;
KILUCR=20;

% Reactivation of esterase (1/h)
KRBBE=0.0014;
KRBCE=0.014;
KRBCR=0.014;
KRBLBE=0.0014;
KRBLCE=0.014;
KRBLCR=0.014;
KRDBE=0.0014;
KRDCE=0.014;
KRDCR=0.014;
KRHBE=0.0014;
KRHCE=0.014;
KRHCR=0.014;
KRRBCE=0.014;
KRLUBE=0.0014;
KRLUCE0=0.014;
KRLUCR=0.014;

% Enzyme turnover rate (substrate hydrolysis/h/active site) (Maxwell 1987)
TRCE=1.17e7;
TRCR=1.086e5;
TRBE=3.66e6;

% Blood flows (L/h/kg tissue)
QBC=30.6;	% Price 2003
QDC=85.2;	% Luecke 2007
QFC=1.45;	% Luecke 2007, Cowles 1971, Price 2003
QHC=50.4;	% Hepatic art, Price 2003
QSC=1.8;	% Bone marrow, Price 2003
QRC=61.8;	% Adreanal/spleen mean, Luecke 2007
SAF=1e-99;
QPC=27.75;
QSKC=12;  %Approx skin blood flow to skin /kg of tissue

% turn off all model variability terms
VMLV=0.0;
VMBLV=0.0;
VMHCPV=0.0;
VMHHCOV=0.0;
VINTTV=0.0;
VINTOV=0.0;
KIRBCEV=0.0;
QHCV=0.0;
HCTV=0.0;
HECEV=0.0;
KRHCRV=0.0;
KRRBCEV=0.0;
VHCV=0.0;
KSIV=0.0;
KDRBCEV=0;
FATVAR=0.;
VBLV=0.0;
VHCV=0.0;
KUNCERT=0.0;

start @nocallback


[Federal Register: August 12, 2010 (Volume 75, Number 155)]
[Notices]
[Page 49016-49017]
[DOCID:fr12au10-102]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Notice of Public Availability of the Final Environmental
Assessment (EA) and Finding of No Significant Impact/Record of Decision
(FONSI/ROD) Signed August 2, 2010, for the Evaluation of the Potential
Environmental Impacts Associated With the Proposed Relocation of the
Bowman County Airport (Airport) in Bowman County, ND.

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Notice of availability of a final EA and FONSI/ROD for the
evaluation of the potential environmental impacts associated with the
proposed relocation of the Bowman County Airport in Bowman County,
North Dakota.

-----------------------------------------------------------------------

SUMMARY: The FAA has made available the final EA and FONSI/ROD for the
proposed relocation of the Bowman County Airport. The EA was prepared
in accordance with the National Environmental Policy Act (NEPA) of
1969, as amended, FAA Orders 1050.1E, ``Environmental Impacts: Policies
and Procedures'' and FAA Order 5050.4B, ``NEPA Implementing
Instructions for Airport Actions.''
    Point of Contact: Ms. Patricia Dressler, Environmental Protection
Specialist, FAA Bismarck ADO, Building 23B, 2301 University Drive,
Bismarck, North Dakota 58504. Telephone number<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The FAA has issued a final EA and FONSI/ROD
that evaluated the potential environmental impacts associated with the
proposed relocation of the Bowman County Airport located in Bowman
County, North Dakota. Based on the analysis contained in the final EA,
the FAA has determined that the selected alternative has no associated
significant impacts to resources identified in accordance with FAA
Order 1050.1E, Environmental Impacts: Policies and Procedures and FAA
Order 5054.4B, National Environmental Policy Act Implementing
Instructions for Airport Actions. Therefore, no environmental impact
statement will be prepared. The current Bowman County Airport has
deficiencies in meeting current and future large aircraft demand (60,
000 pounds or less with 75 percent of these large aircraft at 60
percent useful load), the Runway Protection Zone, Runway Objective Free
Area, wind coverage, and surrounding incompatible land use. Eight
alternatives were studied for airspace feasibility and meeting the
purpose and need. Five of the eight alternatives (three on site and two
new locations) were reviewed, analyzed, and discarded due to the degree
of environmental impacts or not meeting airspace requirements. A
detailed discussion is in the Alternatives Discarded Section of the
FONSI/ROD. The selected alternative is one of three (a no action and
two off site locations) considered in the final EA. The selected
alternative consists of addressing the identified deficiencies and
relocating the Bowman County Airport. The new airport location is
approximately 3.5 miles east of Bowman and just south of US Highway 12.
The Bowman County Airport Authority will construct, operate, and
maintain the new airport. Decommissioning of the existing airport will
occur upon activation of the new airport. The selected alternative
includes the: (1) Unconditional approval of the Airport Layout Plan
(ALP) for the development listed in the EA and the decision document.
(2) Issue

final airspace determinations for the development on the ALP. (3)
Eligibility for Federal grants-in-aid funds for eligible items. (4) FAA
Finding of ``No Historic Properties Affected'' for the proposed action.
(5) FAA Finding of ``No Effect'' to threatened and endangered species.
(6) FAA Finding of ``No Impact'' to floodplains. (7) Wetland finding
that there is no practicable alternative to such construction and the
proposed action includes all practicable measures to minimize harm to
wetlands. (8) Environmental clearance for disposal of land no longer
needed for airport purposes. (9) Appropriate permits and mitigation
will be needed before disbursing Federal funds.
    These documents will be available for public review during normal
business hours at Bldg. 23B, FAA Bismarck ADO, 2301 University Drive,
Bismarck, North Dakota, Bowman Regional Public Library, 18 East Divide
Street, Bowman, ND 58623, and at the Bowman County Airport Authority,
14686 Highway 12, Bowman, ND 58623.

    Issued in Bismarck, North Dakota, August 2, 2010.
Steve Obenauer,
Manager, Bismarck Airport District Office FAA, Great Lakes Region.
[FR Doc. 2010-19920 Filed 8-11-10; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 77, Number 187 (Wednesday, September 26, 2012)]
[Notices]
[Pages 59225-59226]
[FR Doc No: 2012-23601]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Proposed Collection; Comment Request

Upon Written Request, Copies Available From: U.S. Securities and
Exchange

Commission, Office of Investor Education and Advocacy, Washington, DC
20549-0213

Extension:
    Rule 17Ad-17, OMB Control No. 3235-0469, SEC File No. 270-412.

    Notice is hereby given that pursuant to the Paperwork Reduction Act
of 1995 (44 U.S.C. 3501 et seq.), the Securities and Exchange
Commission (``Commission'') is soliciting comments on the collection of
information summarized below. The Commission plans to submit this
existing collection of information to the Office of Management and
Budget for extension and approval.
    Rule 17Ad-17 (17 CFR 240.17Ad-17) requires approximately 477
registered transfer agents to conduct searches using third party
database vendors to attempt to locate lost security holders under the
Securities Exchange Act of 1934 (15 U.S.C. 78a et seq). These
recordkeeping requirements assist the Commission and other regulatory
agencies with monitoring transfer agents and ensuring compliance with
the rule. We estimate that the average number of hours necessary for
each transfer agent to comply with Rule 17Ad-17 is five hours annually.
The total burden is approximately 2,385 hours annually for all transfer
agents. The cost of compliance for each individual transfer agent
depends on the number of lost accounts for which it is responsible.
Based on information received from transfer agents, we estimate that
the annual cost industry-wide is $238,500.
    Written comments are invited on: (a) Whether the proposed
collection of information is necessary for the proper performance of
the functions of the agency, including whether the information shall
have practical utility; (b) the accuracy of the agency's estimates of
the burden of the proposed collection of information; (c) ways to
enhance the quality, utility, and clarity of the information to be
collected; and (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology.
Consideration will be given to comments and suggestions submitted in
writing within 60 days of this publication.
    The Commission may not conduct or sponsor a collection of
information unless it displays a currently valid control number. No
person shall be subject to any penalty for failing to comply with a
collection of information subject to the PRA that does not display a
valid Office of Management and Budget (OMB) control number.
    Please direct your written comments to: Thomas Bayer, Director/
Chief Information Officer, Securities and Exchange Commission, c/o Remi
Pavlik-Simon, 6432 General Green Way, Alexandria, Virginia 22312 or
send an email to<EMAIL_ADDRESS>
    Dated: September 20, 2012.
Kevin M. O'Neill,
Deputy Secretary.
[FR Doc. 2012-23601 Filed 9-25-12; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 77, Number 30 (Tuesday, February 14, 2012)]
[Notices]
[Pages 8310-8312]
[FR Doc No: 2012-3332]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-66358; File No. SR-BATS-2012-006]

Self-Regulatory Organizations; BATS Exchange, Inc.; Notice of
Filing and Immediate Effectiveness of a Proposed Rule Change Related to
Fees for Use of BATS Exchange, Inc.

February 8, 2012.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(the ``Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby given
that on February 1, 2012, BATS Exchange, Inc. (the ``Exchange'' or
``BATS'') filed with the Securities and Exchange Commission
(``Commission'') the proposed rule change as described in Items I, II,
and III below, which Items have been prepared by the Exchange. The
Exchange has designated the proposed rule change as one establishing or
changing a member due, fee, or other charge imposed by the Exchange
under Section 19(b)(3)(A)(ii) of the Act \3\ and Rule 19b-4(f)(2)
thereunder,\4\ which renders the proposed rule change effective upon
filing with the Commission. The Commission is publishing this notice to
solicit comments on the proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \4\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes [sic] amend the fee schedule applicable to
Members \5\ and non-members of the Exchange pursuant to BATS Rules
15.1(a) and (c). Changes will become operative on February 1, 2012.
---------------------------------------------------------------------------

    \5\ A Member is any registered broker or dealer that has been
admitted to membership in the Exchange.
---------------------------------------------------------------------------

    The text of the proposed rule change is available at the Exchange's
Web site at http://www.batstrading.com, at the principal office of the
Exchange, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
Sections A, B, and C below, of the most significant parts of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange proposes to modify the ``Options Pricing'' section of
its fee schedule to change pricing with respect to orders routed to
NASDAQ OMX PHLX LLC (``PHLX''). PHLX has recently introduced increases
to its rates to remove liquidity in specified symbols \6\ identified by
the Exchange as

Make/Take issues (identified as ``Select Symbols'' at PHLX).\7\
Further, PHLX has recently announced an increase to its current fee of
$0.31 per contract to $0.39 per contract for customer orders that
remove liquidity in Make/Take issues.\8\ The Exchange currently charges
certain flat rates for routing to other options exchanges that have
been placed into three groups based on the approximate cost of routing
to such venues. The grouping of away options exchanges is based on the
cost of transaction fees assessed by each venue as well as costs to the
Exchange for routing (i.e., clearing fees, infrastructure costs, etc.).
The Exchange currently assesses fees of $0.30 per contract for Customer
\9\ orders and $0.55 per contract for Professional,\10\ Firm or Market
Maker \11\ orders routed to PHLX in Make/Take issues.\12\ At the
current rates, the Exchange is not currently covering its costs on
Customer orders routed to PHLX in Make/Take issues, based on the
existing base rate of $0.31 per contract plus additional costs incurred
by the Exchange. With the proposal by PHLX to increase fees for
Customer orders that remove liquidity to $0.39 per share, the Exchange
will be even further from the cost of routing customer orders to PHLX
if the Exchange continues to charge $0.30 per contract. In order to
better approximate the cost to the Exchange of routing Customer orders
to PHLX, the Exchange proposes to place PHLX in the away options
exchange grouping along with the Nasdaq Options Market (``NOM''), C2
Options Exchange, Incorporated (``C2''), and NYSE Arca Options
(``Arca'') in Make/Take issues. Accordingly, the Exchange proposes to
charge a fee of $0.50 per contract for Customer orders and to continue
to charge $0.55 per contract for Professional, Firm, or Market Maker
orders routed to and executed at PHLX.
---------------------------------------------------------------------------

    \6\ See Securities Exchange Act Release No. 66100 (January 4,
2012), 77 FR 1532 (January 10, 2012) (SR-Phlx-2011-185) (notice of
filing and immediate effectiveness of proposal to modify fees,
including an increase to the Customer Fee for Removing Liquidity
from $0.29 per contract to $0.31 per contract); Securities Exchange
Act Release No. 65940 (December 12, 2011), 76 FR 78322 (December 16,
2011) (SR-Phlx-2011-162) (notice of filing and immediate
effectiveness of proposal to modify fees, including an increase to
the Customer Fee for Removing Liquidity from $0.25 per contract to
$0.29 per contract).
    \7\ As defined on the fee schedule, Make/Take pricing refers to
executions at the identified exchange under which ``Post Liquidity''
or ``Maker'' rebates (``Make'') are credited by that exchange and
``Take Liquidity'' or ``Taker'' fees (``Take'') are charged by that
exchange.
    \8\ See Options Trader Alert 2012-4, ``PHLX and NOM
Announce Updated Pricing for Customer Orders,'' January 25, 2012.
    \9\ As defined on the Exchange's fee schedule, a Customer order
refers to an order identified by a Member for clearing in the
Customer range at the Options Clearing Corporation (``OCC''),
excluding any transaction for a ``Professional'' as defined in
Exchange Rule 16.1.
    \10\ The term ``Professional'' is defined in Exchange Rule 16.1
to mean any person or entity that (A) is not a broker or dealer in
securities, and (B) places more than 390 orders in listed options
per day on average during a calendar month for its own beneficial
account(s).
    \11\ As defined on the Exchange's fee schedule, the terms
``Firm'' and ``Market Maker'' apply to any transaction identified by
a member for clearing in the Firm or Market Maker range,
respectively, at the OCC.
    \12\ As defined on the fee schedule, Make/Take pricing refers to
executions at the identified exchange under which ``Post Liquidity''
or ``Maker'' rebates (``Make'') are credited by that exchange and
``Take Liquidity'' or ``Taker'' fees (``Take'') are charged by that
exchange.
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that the proposed rule change is consistent
with the requirements of the Act and the rules and regulations
thereunder that are applicable to a national securities exchange, and,
in particular, with the requirements of Section 6 of the Act.\13\
Specifically, the Exchange believes that the proposed rule change is
consistent with Section 6(b)(4) of the Act,\14\ in that it provides for
the equitable allocation of reasonable dues, fees and other charges
among members and other persons using any facility or system which the
Exchange operates or controls. The Exchange notes that it operates in a
highly competitive market in which market participants can readily
direct order flow to competing venues if they deem fee levels at a
particular venue to be excessive. The Exchange also notes that with
respect to the change proposed in this filing, although routing options
are available to all Users, Users are not required to use the
Exchange's routing services, but instead, the Exchange's routing
services are completely optional. Members can manage their own routing
to different options exchanges or can utilize a myriad of other routing
solutions that are available to market participants.
---------------------------------------------------------------------------

    \13\ 15 U.S.C. 78f.
    \14\ 15 U.S.C. 78f(b)(4).
---------------------------------------------------------------------------

    The Exchange believes that its proposal to modify routing fees to
PHLX is reasonable because the modified fee is a better approximation
of the cost to the Exchange for routing Customer orders to PHLX. The
Exchange believes that its flat fee structure for orders routed to
various venues is a fair and equitable approach to pricing, as it
provides certainty with respect to execution fees at groups of away
options exchanges. Under its flat fee structure, the Exchange has
previously operated at a slight loss for Customer orders routed to and
executed at PHLX. The Exchange believes that the proposed change will
allow it to recoup and better cover its costs of providing routing
services going forward. The Exchange also believes that the proposed
fees for orders routed to and executed at PHLX are fair and equitable
and not unreasonably discriminatory in that they apply equally to all
Exchange Users.

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change imposes
any burden on competition.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants or Others

    No written comments were solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Pursuant to Section 19(b)(3)(A)(ii) of the Act \15\ and Rule 19b-
4(f)(2) thereunder,\16\ the Exchange has designated this proposal as
establishing or changing a due, fee, or other charge applicable to the
Exchange's Members and non-members, which renders the proposed rule
change effective upon filing.
---------------------------------------------------------------------------

    \15\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \16\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-BATS-2012-006 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-BATS-2012-006. This file
number should be included on the subject line if email is used. To help
the Commission process and review your comments more efficiently,
please use only one method. The Commission will

post all comments on the Commission's Internet Web site (http://www.sec.gov/rules/sro/shtml). Copies of the submission, all subsequent
amendments, all written statements with respect to the proposed rule
change that are filed with the Commission, and all written
communications relating to the proposed rule change between the
Commission and any person, other than those that may be withheld from
the public in accordance with the provisions of 5 U.S.C. 552, will be
available for Web site viewing and printing in the Commission's Public
Reference Room, 100 F Street NE., Washington, DC 20549, on official
business days between the hours of 10 a.m. and 3 p.m. Copies of such
filing will also be available for inspection and copying at the
principal office of the Exchange. All comments received will be posted
without change; the Commission does not edit personal identifying
information from submissions. You should submit only information that
you wish to make available publicly. All submissions should refer to
File No. SR-BATS-2012-006 and should be submitted on or before March 6,
2012.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\17\
---------------------------------------------------------------------------

    \17\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Kevin M. O'Neill,
Deputy Secretary.
[FR Doc. 2012-3332 Filed 2-13-12; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 86, Number 195 (Wednesday, October 13, 2021)]
[Notices]
[Page 56924]
[FR Doc No: 2021-22171]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2088-083]

South Feather Water and Power Agency; Notice of Application for
Approval of Contract for the Sale of Power Under Section 22 of the
Federal Power Act

    Take notice that on September 3, 2021, South Feather Water and
Power Agency (SFWPA) filed with the Commission an application for
approval of a contract for the sale of power from its licensed South
Feather Hydroelectric Project No. 2088 for a period beyond the
expiration of its existing license for the project. The project is
located on the South Fork Feather River, Lost Creek, and Slate Creek,
in Butte, Yuba, and Plumas Counties, California.
    Section 22 of the Federal Power Act, 16 U.S.C. 815, provides that
contracts for the sale and delivery of power for periods extending
beyond the termination date of a license may be entered into upon the
joint approval of the Commission and the appropriate state public
service commission or other similar authority in the state in which the
sale or delivery of power is made.
    Any person desiring to intervene or to protest this filing must
file in accordance with Rules 211 and 214 of the Commission's Rules of
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be
considered by the Commission in determining the appropriate action to
be taken, but will not serve to make protestants parties to the
proceeding. Any person wishing to become a party must file a notice of
intervention or motion to intervene, as appropriate. Such notices,
motions, or protests must be filed on or before the comment date.
Anyone filing a motion to intervene or protest must serve a copy of
that document on the Petitioner.
    The Commission strongly encourages electronic filing. Please file
comments, motions to intervene, notices of intent, and competing
applications using the Commission's eFiling system at http://www.ferc.gov/docs-filing/efiling.asp. Commenters can submit brief
comments up to 6,000 characters, without prior registration, using the
eComment system at http://www.ferc.gov/docs-filing/ecomment.asp. You
must include your name and contact information at the end of your
comments. In lieu of electronic filing, you may submit a paper copy.
Submissions sent via the U.S. Postal Service must be addressed to:
Kimberly D. Bose, Secretary, Federal Energy Regulatory Commission, 888
First Street NE, Room 1A, Washington, DC 20426. Submissions sent via
any other carrier must be addressed to: Kimberly D. Bose, Secretary,
Federal Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville,
Maryland 20852. The first page of any filing should include docket
number P-15226-000.
    More information about this project, including a copy of the
application, can be viewed or printed on the ``eLibrary'' link of
Commission's website at http://www.ferc.gov/docs-filing/elibrary.asp.
Enter the docket number (P-15226) in the docket number field to access
the document. For assistance, contact FERC Online Support.
    Comment Date: 5:00 p.m. Eastern Time on November 4, 2021.

    Dated: October 5, 2021.
Kimberly D. Bose,
Secretary.
[FR Doc. 2021-22171 Filed 10-12-21; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register: September 4, 2009 (Volume 74, Number 171)]
[Notices]
[Page 45883-45884]
[DOCID:fr04se09-87]

-----------------------------------------------------------------------

DEPARTMENT OF LABOR

Occupational Safety and Health Administration

[Docket No. OSHA-2009-0017]

The Standard on Personal Protective Equipment (PPE) for Shipyard
Employment; Extension of the Office of Management and Budget's (OMB)
Approval of Information Collection (Paperwork) Requirements

AGENCY: Occupational Safety and Health Administration (OSHA), Labor.

ACTION: Request for public comment.

-----------------------------------------------------------------------

SUMMARY: OSHA solicits public comments concerning its proposal to
extend OMB approval of the information collection requirements
specified in the Standard on Personal Protective Equipment (PPE) for
Shipyard Employment (29 CFR part 1915, subpart I).

DATES: Comments must be submitted (postmarked, sent, or received) by
November 3, 2009.

ADDRESSES:
    Electronically: You may submit comments and attachments
electronically at http://www.regulations.gov, which is the Federal
eRulemaking Portal. Follow the instructions online for submitting
comments.
    Facsimile: If your comments, including attachments, are not longer
than 10 pages, you may fax them to the OSHA Docket Office at (202) 693-
1648.
    Mail, hand delivery, express mail, messenger, or courier service:
When using this method, you must submit three copies of your comments
and attachments to the OSHA Docket Office, Docket No. OSHA-2009-0017,
U.S. Department of Labor, Occupational Safety and Health
Administration, Room N-2625, 200 Constitution Avenue, NW., Washington,
DC 20210. Deliveries (hand, express mail, messenger, and courier
service) are accepted during the Department of Labor's and Docket
Office's normal business hours, 8:15 a.m. to 4:45 p.m., e.t.
    Instructions: All submissions must include the Agency name and OSHA
docket number for the Information Collection Request (ICR) (OSHA-2009-
0017). All comments, including any personal information you provide,
are placed in the public docket without change, and may be made
available online at http://www.regulations.gov. For further information
on submitting comments see the ``Public Participation'' heading in the
section of this notice titled SUPPLEMENTARY INFORMATION.
    Docket: To read or download comments or other material in the
docket, go to http://www.regulations.gov or the OSHA Docket Office at
the address above. All documents in the docket (including this Federal
Register notice) are listed in the http://www.regulations.gov index;
however, some information (e.g., copyrighted material) is not publicly
available to read or download through the Web site. All submissions,
including copyrighted material, are available for inspection and
copying at the OSHA Docket Office. You may also contact Theda Kenney at
the address below to obtain a copy of the ICR.

FOR FURTHER INFORMATION CONTACT: Theda Kenney or Todd Owen, Directorate
of Standards and Guidance, OSHA, U.S. Department of Labor, Room N-3609,
200 Constitution Avenue, NW., Washington, DC 20210; telephone (202)
693-2222.

SUPPLEMENTARY INFORMATION:

I. Background

    The Department of Labor, as part of its continuing effort to reduce
paperwork and respondent (i.e., employer) burden, conducts a
preclearance consultation program to provide the public with an
opportunity to comment on proposed and continuing information
collection requirements in accordance with the Paperwork Reduction Act
of 1995 (44 U.S.C. 3506(c)(2)(A)). This program ensures that
information is in the desired format, reporting burden (time and costs)
is minimal, collection instruments are clearly understood, and OSHA's
estimate of the information collection burden is accurate. The
Occupational Safety and Health Act of 1970 (the OSH Act) (29 U.S.C. 651
et seq.) authorizes information collection by employers as necessary or
appropriate for enforcement of the OSH Act or for developing
information regarding the causes and prevention of occupational
injuries, illnesses, and accidents (29 U.S.C. 657). The OSH Act also
requires that OSHA obtain such information with minimum burden upon
employers, especially those operating small businesses, and to reduce
to the maximum extent feasible unnecessary duplication of efforts in
obtaining information (29 U.S.C. 657).
    Subpart I specifies several paperwork requirements, which are
described below.
    (A) Hazard Assessment and Verification (Sec.  1915.152(b)). Section
1915.152(b) requires the employer to assess work activities to
determine whether there are hazards present, or likely to be present,
which necessitate the worker's use of PPE. If such hazards are present,
or likely to be present, the employer must: (1) Select the type of PPE
that will protect the affected workers from the hazards identified in
the occupational hazard assessment; (2) communicate selection decisions
to affected workers; (3) select PPE that properly fits each affected
worker; and (4) verify that the required occupational hazard assessment
has been performed. The verification must contain the following
information: Occupation or trade assessed, the date(s) of the hazard
assessment, and the name of the person performing the hazard
assessment.
    (B) Training and Verification (Sec.  1915.152(e)). Section
1910.152(e) requires that employers provide training for each worker
who is required to wear PPE (Sec.  1915.152(e)(1)). Paragraph (e)(3)
requires that employers also provide retraining when there are certain
changes in workplace conditions or there is reason to believe that any
previously trained worker does not have the understanding or skill to
use PPE properly. Circumstances where such retraining is required
include changes in the workplace that render prior training obsolete,
certain changes in the types of PPE used, and inadequacies in the
worker's knowledge or use of PPE that indicate the worker had not
retained the requisite understanding or skill.
    Paragraph (e)(4) requires that the employer verify that each
affected worker has received the required PPE training. The
verification must contain the following information: Name of each
worker trained, the date(s) of training,

and the type of training the worker received.
    The standards on PPE protection for the eyes and face (Sec.
1915.153), head (Sec.  1915.155), feet (Sec.  1915.156), hands and body
(Sec.  1915.157), lifesaving equipment (Sec.  1915.158), personal fall
arrest systems (Sec.  1915.159), and positioning device systems (Sec.
1915.160) do not contain any separate information collection
requirements.

II. Special Issues for Comment

    OSHA has a particular interest in comments on the following issues:
     Whether the proposed information collection requirements
are necessary for the proper performance of the Agency's functions,
including whether the information is useful;
     The accuracy of OSHA's estimate of the burden (time and
costs) of the information collection requirements, including the
validity of the methodology and assumptions used;
     The quality, utility, and clarity of the information
collected; and
     Ways to minimize the burden on employers who must comply;
for example, by using automated or other technological information
collection and transmission techniques.

III. Proposed Actions

    OSHA is requesting that OMB extend its approval of the collection
of information requirements contained in the Standard on Personal
Protective Equipment (PPE) for Shipyard Employment (29 CFR part 1915,
subpart I). The Agency is requesting an adjustment to the burden hours
from 2,041 to 2,827 hours (an increase of 786 hours). The increase in
the burden hours can be attributed to the number of existing workers
increasing from 62,191 to 86,764.
    OSHA will summarize the comments submitted in response to this
notice, and will include this summary in its request to OMB to extend
the approval of the information collection requirements contained in
the Standard on Personal Protective Equipment (PPE) for Shipyard
Employment (29 CFR Part 1915, Subpart I).

    Type of Review: Extension of a currently approved collection.
    Title: Personal Protective Equipment Standard for Shipyard
Employment (29 CFR part 1915, subpart I).
    OMB Number: 1218-0215.
    Affected Public: Business or other for-profits.
    Total Responses: 108,335.
    Frequency: On occasion.
    Estimated Time per Response: Varies from 1 minute (.02 hour) for
employers to maintain the certification record for each worker to 5
minutes to record the hazard assessment for each occupation covered.
    Total Burden Hours: 2,827.
    Estimated Cost (Operation and Maintenance): $0.

IV. Public Participation--Submission of Comments on This Notice and
Internet Access to Comments and Submissions

    You may submit comments in response to this document as follows:
(1) Electronically at http://www.regulations.gov, which is the Federal
e-Rulemaking Portal; (2) by facsimile (FAX); or (3) by hard copy. All
comments, attachments, and other material must identify the Agency name
and OSHA docket number for the ICR (Docket No. OSHA-2009-0017). You may
supplement electronic submissions by uploading document files
electronically. If you wish to mail additional materials in reference
to an electronic or facsimile submission, you must submit them to the
OSHA Docket Office (see the section of this notice titled ADDRESSES).
The additional materials must clearly identify your electronic comments
by your name, date, and the docket number so the Agency can attach them
to your comments.
    Because of security procedures, the use of regular mail may cause a
significant delay in the receipt of comments. For information about
security procedures concerning the delivery of materials by hand,
express delivery, messenger, or courier service, please contact the
OSHA Docket Office at<PHONE_NUMBER> (TTY<PHONE_NUMBER>).
    Comments and submissions are posted without change at http://
www.regulations.gov. Therefore, OSHA cautions commenters about
submitting personal information such as social security numbers and
date of birth. Although all submissions are listed in the http://
www.regulations.gov index, some information (e.g., copyrighted
material) is not publically available to read or download through this
Web site. All submissions, including copyrighted material, are
available for inspection and copying at the OSHA Docket Office.
Information on using the http://www.regulations.gov Web site to submit
comments and access the docket is available through the Web site's
``User Tips'' link. Contact the OSHA Docket Office for information
about materials not available through the Web site, and for assistance
in using the Internet to locate docket submissions.

V. Authority and Signature

    Jordan Barab, Acting Assistant Secretary of Labor for Occupational
Safety and Health, directed the preparation of this notice. The
authority for this notice is the Paperwork Reduction Act of 1995 (44
U.S.C. 3506 et seq.) and Secretary of Labor's Order No. 5-2007 (72 FR
31160).

    Signed at Washington, DC, this 28th day of August 2009.
Jordan Barab,
Acting Assistant Secretary of Labor for Occupational Safety and Health.
[FR Doc. E9-21332 Filed 9-3-09; 8:45 am]

BILLING CODE 4510-26-P


[Federal Register: February 13, 2008 (Volume 73, Number 30)] [CORRECTIONS]                [Page 8408] [DOCID:fr13fe08-179]

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

[EPA-HQ-OAR-2005-0526; FRL-8508-6] RIN 2060-AN21

  National Emission Standards for Hazardous Air Pollutants: Paint  Stripping and Miscellaneous Surface Coating Operations at Area Sources

Correction

    In rule document E7-24718 beginning on page 1738 in the issue of  Wednesday, January 9, 2008, make the following corrections:

Sec.  63.11173  [Corrected]

    1. On page 1761, in the second column, in Sec.  63.11173(b), in the  seventh line from the bottom, ``more'' should read ``less''.     2. On the same page, in the same column, in the same section, in  the same paragraph, in the fifth line from the bottom, ``management  practices'' should read ``requirements''.

[FR Doc. Z7-24718 Filed 2-12-08; 8:45 am]

BILLING CODE 1505-01-D


[Federal Register Volume 84, Number 96 (Friday, May 17, 2019)]
[Notices]
[Pages 22482-22484]
[FR Doc No: 2019-10238]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP19-125-000]

Gulf South Pipeline Company, LP; Notice of Intent To Prepare an
Environmental Assessment for the Proposed Index 99 Expansion Project
and Request for Comments on Environmental Issues

    The staff of the Federal Energy Regulatory Commission (FERC or
Commission) will prepare an environmental assessment (EA) that will
discuss the environmental impacts of the Index 99 Expansion Project
involving construction and operation of facilities by Gulf South
Pipeline Company (Gulf South) in San Augustine and Sabine Counties,
Texas and

Bienville Parish, Louisiana. The Commission will use this EA in its
decision-making process to determine whether the project is in the
public convenience and necessity.
    This notice announces the opening of the scoping process the
Commission will use to gather input from the public and interested
agencies about issues regarding the project. The National Environmental
Policy Act (NEPA) requires the Commission to take into account the
environmental impacts that could result from its action whenever it
considers the issuance of a Certificate of Public Convenience and
Necessity. NEPA also requires the Commission to discover concerns the
public may have about proposals. This process is referred to as
``scoping.'' The main goal of the scoping process is to focus the
analysis in the EA on the important environmental issues. By this
notice, the Commission requests public comments on the scope of issues
to address in the EA. To ensure that your comments are timely and
properly recorded, please submit your comments so that the Commission
receives them in Washington, DC on or before 5:00 p.m. Eastern Time on
June 12, 2019.
    You can make a difference by submitting your specific comments or
concerns about the project. Your comments should focus on the potential
environmental effects, reasonable alternatives, and measures to avoid
or lessen environmental impacts. Your input will help the Commission
staff determine what issues they need to evaluate in the EA. Commission
staff will consider all filed comments during the preparation of the
EA.
    If you sent comments on this project to the Commission before the
opening of this docket on March 29, 2019, you will need to file those
comments in Docket No. CP19-125-000 to ensure they are considered as
part of this proceeding.
    This notice is being sent to the Commission's current environmental
mailing list for this project. State and local government
representatives should notify their constituents of this proposed
project and encourage them to comment on their areas of concern.
    If you are a landowner receiving this notice, a pipeline company
representative may contact you about the acquisition of an easement to
construct, operate, and maintain the proposed facilities. The company
would seek to negotiate a mutually acceptable easement agreement. You
are not required to enter into an agreement. However, if the Commission
approves the project, that approval conveys with it the right of
eminent domain. Therefore, if you and the company do not reach an
easement agreement, the pipeline company could initiate condemnation
proceedings in court. In such instances, compensation would be
determined by a judge in accordance with state law.
    Gulf South provided landowners with a fact sheet prepared by the
FERC entitled ``An Interstate Natural Gas Facility On My Land? What Do
I Need To Know?'' This fact sheet addresses a number of typically asked
questions, including the use of eminent domain and how to participate
in the Commission's proceedings. It is also available for viewing on
the FERC website (www.ferc.gov) at https://www.ferc.gov/resources/guides/gas/gas.pdf.

Public Participation

    The Commission offers a free service called eSubscription which
makes it easy to stay informed of all issuances and submittals
regarding the dockets/projects to which you subscribe. These instant
email notifications are the fastest way to receive notification and
provide a link to the document files which can reduce the amount of
time you spend researching proceedings. To sign up go to www.ferc.gov/docs-filing/esubscription.asp.
    For your convenience, there are three methods you can use to submit
your comments to the Commission. The Commission encourages electronic
filing of comments and has staff available to assist you at (866) 208-
3676 or<EMAIL_ADDRESS>Please carefully follow these
instructions so that your comments are properly recorded.
    (1) You can file your comments electronically using the eComment
feature, which is located on the Commission's website (www.ferc.gov)
under the link to Documents and Filings. Using eComment is an easy
method for submitting brief, text-only comments on a project;
    (2) You can file your comments electronically by using the eFiling
feature, which is located on the Commission's website (www.ferc.gov)
under the link to Documents and Filings. With eFiling, you can provide
comments in a variety of formats by attaching them as a file with your
submission. New eFiling users must first create an account by clicking
on ``eRegister.'' You will be asked to select the type of filing you
are making; a comment on a particular project is considered a ``Comment
on a Filing''; or
    (3) You can file a paper copy of your comments by mailing them to
the following address. Be sure to reference the project docket number
(CP19-125-000) with your submission: Kimberly D. Bose, Secretary,
Federal Energy Regulatory Commission, 888 First Street NE, Room 1A,
Washington, DC 20426.

Summary of the Proposed Project

    The Index 99 Expansion Project would consist of the construction of
a new pipeline, new launcher and receiver facilities, and a new
mainline valve, and modifications to an existing compressor station.
All project components are in Texas and Louisiana. The project would
provide about 500,000 dekatherms per day (Dth/d) of new natural gas
firm transportation service to markets along the Gulf Coast region, as
well as provide for an additional 250,000 Dth/d of capacity to Gulf
South's existing facilities in northern Louisiana, for a total maximum
daily quantity of 750,000 Dth/d.
    The project would consist of the following facilities:
     Installation of approximately 22 miles of new 30-inch-
diameter pipeline (Index 99L), including cathodic protection along the
proposed pipeline, in San Augustine and Sabine Counties, Texas.
     Installation of a pig \1\ receiver at the intersection of
the new Index 99L pipeline and Gulf South's existing Index 99 System,
in San Augustine County, Texas.
---------------------------------------------------------------------------

    \1\ A ``pig'' is a tool that the pipeline company inserts into
and pushes through the pipeline for cleaning the pipeline,
conducting internal inspections, or other purposes.
---------------------------------------------------------------------------

     Installation of a pig launcher at the intersection of the
new Index 99L pipeline and Gulf South's existing Index 99 System and
Index 129 Legacy System, in Sabine County, Texas.
     Installation of one new mainline valve assembly along the
new Index 99L pipeline, in San Augustine County, Texas.
     Installation of approximately 250 feet of new 24-inch-
diameter station pipe and a 24-inch-diameter pressure control valve
along the new 24-inch-diameter station pipe at the existing Hall Summit
Compressor Station in Bienville Parish, Louisiana.
    The general location of the project facilities is shown in appendix
1.\2\
---------------------------------------------------------------------------

    \2\ The appendices referenced in this notice will not appear in
the Federal Register. Copies of appendices were sent to all those
receiving this notice in the mail and are available at www.ferc.gov
using the link called ``eLibrary'' or from the Commission's Public
Reference Room, 888 First Street NE, Washington, DC 20426, or call
(202) 502-8371. For instructions on connecting to eLibrary, refer to
the last page of this notice.
---------------------------------------------------------------------------

Land Requirements for Construction

    Construction of the proposed facilities would disturb about 392
acres of land

for the pipeline and the aboveground facilities. Following
construction, Gulf South would maintain about 162 acres for permanent
operation of the project's facilities; the remaining acreage would be
restored and revert to former uses. About 93 percent (20 miles) of the
proposed pipeline route parallels existing pipeline, utility, or road
rights-of-way.

The EA Process

    The EA will discuss impacts that could occur as a result of the
construction and operation of the proposed project under these general
headings:
     Geology and soils;
     water resources and wetlands;
     vegetation and wildlife;
     threatened and endangered species;
     cultural resources;
     land use;
     air quality and noise;
     public safety; and
     cumulative impacts
    Commission staff will also evaluate reasonable alternatives to the
proposed project or portions of the project, and make recommendations
on how to lessen or avoid impacts on the various resource areas.
    The EA will present Commission staffs' independent analysis of the
issues. The EA will be available in electronic format in the public
record through eLibrary \3\ and the Commission's website (https://www.ferc.gov/industries/gas/enviro/eis.asp). If eSubscribed, you will
receive instant email notification when the EA is issued. The EA may be
issued for an allotted public comment period. Commission staff will
consider all comments on the EA before making recommendations to the
Commission. To ensure Commission staff have the opportunity to address
your comments, please carefully follow the instructions in the Public
Participation section, beginning on page 2.
---------------------------------------------------------------------------

    \3\ For instructions on connecting to eLibrary, refer to the
last page of this notice.
---------------------------------------------------------------------------

    With this notice, the Commission is asking agencies with
jurisdiction by law and/or special expertise with respect to the
environmental issues of this project to formally cooperate in the
preparation of the EA.\4\ Agencies that would like to request
cooperating agency status should follow the instructions for filing
comments provided under the Public Participation section of this
notice.
---------------------------------------------------------------------------

    \4\ The Council on Environmental Quality regulations addressing
cooperating agency responsibilities are at Title 40, Code of Federal
Regulations, Part 1501.6.
---------------------------------------------------------------------------

Consultation Under Section 106 of the National Historic Preservation
Act

    In accordance with the Advisory Council on Historic Preservation's
implementing regulations for section 106 of the National Historic
Preservation Act, the Commission is using this notice to initiate
consultation with the applicable State Historic Preservation Offices,
and to solicit their views and those of other government agencies,
interested Indian tribes, and the public on the project's potential
effects on historic properties.\5\ The EA for this project will
document findings on the impacts on historic properties and summarize
the status of consultations under section 106.
---------------------------------------------------------------------------

    \5\ The Advisory Council on Historic Preservation's regulations
are at Title 36, Code of Federal Regulations, Part 800. Those
regulations define historic properties as any prehistoric or
historic district, site, building, structure, or object included in
or eligible for inclusion in the National Register of Historic
Places.
---------------------------------------------------------------------------

Environmental Mailing List

    The environmental mailing list includes federal, state, and local
government representatives and agencies; elected officials;
environmental and public interest groups; Native American Tribes; other
interested parties; and local libraries and newspapers. This list also
includes all affected landowners (as defined in the Commission's
regulations) who are potential right-of-way grantors, whose property
may be used temporarily for project purposes, or who own homes within
certain distances of aboveground facilities, and anyone who submits
comments on the project. Commission staff will update the environmental
mailing list as the analysis proceeds to ensure that Commission notices
related to this environmental review are sent to all individuals,
organizations, and government entities interested in and/or potentially
affected by the proposed project.
    If the Commission issues the EA for an allotted public comment
period, a Notice of Availability of the EA will be sent to the
environmental mailing list and will provide instructions to access the
electronic document on the FERC's website (www.ferc.gov). If you need
to make changes to your name/address, or if you would like to remove
your name from the mailing list, please return the attached ``Mailing
List Update Form'' (appendix 2).

Additional Information

    Additional information about the project is available from the
Commission's Office of External Affairs, at (866) 208-FERC, or on the
FERC website at www.ferc.gov using the eLibrary link. Click on the
eLibrary link, click on ``General Search'' and enter the docket number
in the ``Docket Number'' field, excluding the last three digits (i.e.,
CP19-125). Be sure you have selected an appropriate date range. For
assistance, please contact FERC Online Support at
<EMAIL_ADDRESS>or<PHONE_NUMBER>, or for TTY, contact (202)
502-8659. The eLibrary link also provides access to the texts of all
formal documents issued by the Commission, such as orders, notices, and
rulemakings.
    Public sessions or site visits will be posted on the Commission's
calendar located at www.ferc.gov/EventCalendar/EventsList.aspx along
with other related information.

    Dated: May 13, 2019.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2019-10238 Filed 5-16-19; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register: May 5, 2010 (Volume 75, Number 86)]
[Notices]
[Page 24708-24710]
[DOCID:fr05my10-99]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0198]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Premarket Notification

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on premarket notification.

DATES:  Submit written or electronic comments on the collection of
information by July 6, 2010.

ADDRESSES:  Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccad Dr.,
PI50-400B, Rockville, MD 20850,<PHONE_NUMBER>,
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information,

including each proposed extension of an existing collection of
information, before submitting the collection to OMB for approval. To
comply with this requirement, FDA is publishing notice of the proposed
collection of information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Premarket Notification--21 CFR Part 807, Subpart E--(OMB Control Number
0910-0120)--Extension

    Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the
act) (21 U.S.C. 360(k)) and the implementing regulation under part 807
(21 CFR part 807, subpart E) require a person who intends to market a
medical device to submit a premarket notification submission to FDA at
least 90 days before proposing to begin the introduction or delivery
for introduction into interstate commerce for commercial distribution
of a device intended for human use. Based on the information provided
in the notification, FDA must determine whether the new device is
substantially equivalent to a legally marketed device, as defined in
Sec.  807.92(a)(3). If the device is determined to be not substantially
equivalent to a legally marketed device, it must have an approved
premarket approval application (PMA), Product Development Protocol,
Humanitarian Device Exemption (HDE), Petition for Evaluation of
Automatic Class III Designation (de novo) or be reclassified into class
I or class II before being marketed. FDA makes the final decision of
whether a device is substantially equivalent or not equivalent.
    Section 807.81 states when a premarket notification is required. A
premarket notification is required to be submitted by a person who is:
     Introducing a device to the market for the first time;
     Introducing a device into commercial distribution for the
first time by a person who is required to register; and
     Introducing or reintroducing a device which is
significantly changed or modified in design, components, method of
manufacturer, or the intended use that could affect the safety and
effectiveness of the device.
    Section 807.87 specifies information required in a premarket
notification submission.
    Section 204 of the Food and Drug Administration Modernization Act
(FDAMA) amended section 514 of the act (21 U.S.C. 360d). Amended
section 514 allows FDA to recognize consensus standards developed by
international and national organizations for use in satisfying portions
of device premarket review submissions including premarket
notifications or other requirements. FDA has published and updated the
list of recognized standards regularly since enactment of FDAMA and has
allowed 510(k) submitters to certify conformance to recognized
standards to meet the requirements of Sec.  807.87. Form FDA 3654, the
510(k) Standards Data Form, standardizes the format for submitting
information on consensus standards that a 510(k) submitter chooses to
use as a portion of their premarket notification submission. (The Form
FDA 3654 is not for declarations of conformance to a recognized
standard FDA believes that use of this form will simplify the 510(k)
preparation and review process for 510(k) submitters.
    Form FDA 3514, a summary cover sheet form, assists respondents in
categorizing administrative 510(k) information for submission to FDA.
This form also assists respondents in categorizing information for
other FDA medical device programs such as PMAs, investigational device
exemptions, and HDEs. Under Sec.  807.87(h), each 510(k) submitter must
include in the 510(k) either a summary of the information in the 510(k)
as required by Sec.  807.92 (510(k) summary) or a statement certifying
that the submitter will make available upon request the information in
the 510(k) with certain exceptions as per Sec.  807.93 (510(k)
statement). If the 510(k) submitter includes a 510(k) statement in the
510(k) submission, Sec.  807.93 requires that the official
correspondent of the firm make available within 30 days of a request,
all information included in the submitted premarket notification on
safety and effectiveness. This information will be provided to any
person within 30 days of a request if the device described in the
510(k) submission is determined to be substantially equivalent. The
information provided will be a duplicate of the 510(k) submission
including any safety and effectiveness information, but excluding all
patient identifiers and trade secret and commercial confidential
information.
    According to Sec.  807.90, submitters may request information on
their 510(k) review status 90 days after the initial log-in date of the
510(k). Thereafter, the submitter may request status reports every 30
days following the initial status request. To obtain a 510(k) status
report, the submitter should complete the status request form, Form FDA
3541, and fax it to the Center for Devices and Radiological Health
office identified on the form.
    The most likely respondents to this information collection will be
specification developers and medical device manufacturers.
    FDA estimates the burden of this collection of information as
follows:

                                                     Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                Annual
              21 CFR  Section                 Form  Number         No. of        Frequency  per     Total Annual         Hours per         Total Hours
                                                                 Respondents        Response          Responses          Response
--------------------------------------------------------------------------------------------------------------------------------------------------------
807 subpart E                               ................             3,700                 1             3,700               79              292,300
--------------------------------------------------------------------------------------------------------------------------------------------------------
807.87                                         FDA Form 3514             1,956                 1             1,956                0.5                978
--------------------------------------------------------------------------------------------------------------------------------------------------------
807.90(a)(3)                                   FDA Form 3541               218                 1               218                0.25                55
--------------------------------------------------------------------------------------------------------------------------------------------------------
807.87(d) and (f)                              FDA Form 3654             1,500                 1             1,500               10               15,000
--------------------------------------------------------------------------------------------------------------------------------------------------------

807.93                                      ................             2,000                 1             2,000                0.5              1,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
Totals                                                                                309,333
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

    FDA has based these estimates on conversations with industry and
trade association representatives, and from internal review of the
documents listed in table 1 of this document.

    Dated: April 29, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-10576 Filed 5-4-10; 8:45 am]
BILLING CODE 4160-01-S


Janet Cakir/RTP/USEPA/US

11/15/2007 10:52 AM

To

"Johansson, Robert"<EMAIL_ADDRESS> cc

"King, Heidi R."<EMAIL_ADDRESS>"Schwab, Margo" <EMAIL_ADDRESS>"Johansson, Robert" <EMAIL_ADDRESS>Ron Evans/RTP/USEPA/US@EPA

Subject

Re: Follow Up

Rob,

    Thanks for the list of questions.  Attached are answers.  Please let me know if you have any trouble with the file or have further questions.

Thanks,

Janet

_______________________________________

Janet F. Cakir, Ph.D.

Environmental Protection Specialist

Air Benefits Cost Group

109 TW Alexander Dr., (C439-02)

Research Triangle Park, NC 27711

Tel:<PHONE_NUMBER>

Fax:<PHONE_NUMBER>

email<EMAIL_ADDRESS> "Johansson, Robert"<EMAIL_ADDRESS> 11/07/2007 12:25 PM

To

"Johansson, Robert"<EMAIL_ADDRESS>Janet Cakir/RTP/USEPA/US@EPA, Ron Evans/RTP/USEPA/US@EPA

cc

"King, Heidi R."<EMAIL_ADDRESS>"Schwab, Margo" <EMAIL_ADDRESS> Subject

Follow Up

Hi Janet and Ron,

Please find attached the interagency list of follow up questions from

last week's briefing.

Cheers,

Rob


[Federal Register Volume 87, Number 58 (Friday, March 25, 2022)]
[Notices]
[Page 17080]
[FR Doc No: 2022-06304]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings

    Take notice that the Commission has received the following Natural
Gas Pipeline Rate and Refund Report filings:

Filings Instituting Proceedings

    Docket Numbers: RP22-708-000.
    Applicants: TransCameron Pipeline, LLC.
    Description: Operational Purchases and Sales Report and Waiver
Request of TransCameron Pipeline, LLC.
    Filed Date: 3/18/22.
    Accession Number: 20220318-5193.
    Comment Date: 5 p.m. ET 3/30/22.

    Docket Numbers: RP22-709-000.
    Applicants: TransCameron Pipeline, LLC.
    Description: Annual Fuel Reimbursement Filing and Waiver Request of
TransCameron Pipeline, LLC.
    Filed Date: 3/18/22.
    Accession Number: 20220318-5197.
    Comment Date: 5 p.m. ET 3/30/22.

    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.

Filings in Existing Proceedings

    Docket Numbers: RP17-598-005.
    Applicants: Great Lakes Gas Transmission Limited Partnership.
    Description: Compliance filing: GLGT RP17-598 Amended & Restated
Settlement Filing to be effective N/A.
    Filed Date: 3/18/22.
    Accession Number: 20220318-5097.
    Comment Date: 5 p.m. ET 3/30/22.

    Any person desiring to protest in any the above proceedings must
file in accordance with Rule 211 of the Commission's Regulations (18
CFR 385.211) on or before 5:00 p.m. Eastern time on the specified
comment date.
    The filings are accessible in the Commission's eLibrary system
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying
the docket number.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: March 21, 2022.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2022-06304 Filed 3-24-22; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 85, Number 190 (Wednesday, September 30, 2020)]
[Notices]
[Page 61780]
[FR Doc No: 2020-21725]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Sunshine Act Meetings

TIME AND DATE: Notice is hereby given, pursuant to the provisions of
the Government in the Sunshine Act, Public Law 94-409, that the
Securities and Exchange Commission Fixed Income Market Structure
Advisory Committee will hold a public meeting on October 5, 2020, at
9:30 a.m. (ET).

PLACE: The meeting will be conducted by remote means. Members of the
public may watch the webcast of the meeting on the Commission's website
at www.sec.gov.

STATUS: The meeting will begin at 9:30 a.m. and will be open to the
public via webcast. The Sunshine Act notice is being issued because a
majority of the Commission may attend the meeting.

MATTERS TO BE CONSIDERED: On September 15, 2020, the Commission issued
notice of the Committee meeting (Release No. 34-89868), indicating that
the meeting is open to the public and inviting the public to submit
written comments to the Committee.
    The agenda for the meeting will include a potential recommendation
concerning TRACE identification of electronic trades, subcommittee
observations and lessons learned in the corporate bond market, the bond
fund and ETF market, the technology and e-trading markets, and the
municipal securities markets, as well as member observations of the
fixed income markets.

CONTACT PERSON FOR MORE INFORMATION: For further information, please
contact Vanessa A. Countryman from the Office of the Secretary at (202)
551-5400.

    Dated: September 28, 2020.
Vanessa A. Countryman,
Secretary.
[FR Doc. 2020-21725 Filed 9-28-20; 4:15 pm]
BILLING CODE 8011-01-P